Common Contracts
17 similar Joint Filing Agreement contracts by Biotechnology Value Fund L P
Joint Filing AgreementJoint Filing Agreement • November 9th, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Amendment No. 5 to Schedule 13G dated November 9, 2015 with respect to the shares of Common Stock of ChemoCentryx, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • October 2nd, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated October 2, 2015 with respect to the shares of Common Stock of CTI Biopharma Corp., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • July 10th, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated July 10, 2015 with respect to the shares of Common Shares of Xenon Pharmaceuticals Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • June 5th, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated June 5, 2015 with respect to the shares of Common Stock of GlobeImmune, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • May 8th, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated May 8, 2015 with respect to the shares of Common Stock of Blueprint Medicines Corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • February 17th, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Amendment No. 1 to Schedule 13G dated February 17, 2015 with respect to the shares of Common Stock of Five Prime Therapeutics, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • February 17th, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated February 17, 2015 with respect to the shares of Common Stock of Vitae Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • February 17th, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Amendment No. 3 to Schedule 13G dated February 13, 2015 with respect to the shares of Common Stock of Oncothyreon Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • February 17th, 2015 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Amendment No. 3 to Schedule 13G dated February 13, 2015 with respect to the shares of Common Stock of Regado Biosciences, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • December 24th, 2014 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated December 24, 2014 with respect to the shares of Common Stock of Sophiris Bio, Inc. and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • December 12th, 2014 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated December 10, 2014 with respect to the shares of Common Stock of OncoGenex Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • November 24th, 2014 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated November 24, 2014 with respect to the shares of Common Stock of GTx, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • November 14th, 2014 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated November 14, 2014 with respect to the Common Shares of Xenon Pharmaceuticals Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • November 14th, 2014 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated November 14, 2014 with respect to the shares of Common Stock of Sunesis Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • October 23rd, 2014 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated October 23, 2014 with respect to the shares of Common Stock of Vitae Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • September 12th, 2014 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated September 12, 2014 with respect to the shares of Common Stock of Concert Pharmaceuticals, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • August 11th, 2014 • Biotechnology Value Fund L P • Investment advice
The undersigned hereby agree that the Statement on Schedule 13G dated August 11, 2014 with respect to the shares of Common Stock of Loxo Oncology, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.
